Year: 2019

Paris, November 27, 2019, 8.30pmAB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019AB Science SA (NYSE Euronext – FR0010557264 – AB) is hosting a live webcast on December 2 with key opinion leaders in severe asthma uncontrolled by oral corticosteroids and the role that masitinib may play in treating this disorder.The webcast will feature a presentation by key opinion leaders who will provide:A discussion of current treatment options in severe asthma uncontrolled by oral corticosteroids.An overview of the masitinib clinical results in severe asthma, including more details about the AB07105 Phase 3 study, which had positive top-line data announced on November 7.The masitinib development pathway forward in asthma.The presentation will be followed by a Q&A session with the key opinion leaders...

Paris, 27 novembre 2019, 8h30AB Science tiendra une web conférence sur le masitinibdans l’asthme sévère le lundi 2 décembre 2019AB Science SA (NYSE Euronext – FR0010557264 – AB) tiendra une web conférence le 2 décembre 2019 sur l’asthme sévère non contrôlé par les corticostéroïdes oraux avec les principaux leaders d’opinion de cette maladie et sur le rôle du masitinib comme possible traitement dans cette indication.Durant cette web conférence, les principaux leaders d’opinion présenteront :Les traitements actuels dans l’asthme sévère non contrôlé par les corticostéroïdes oraux.Les résultats antérieurs du mastinib dans l’asthme sévère, et en particulier les résultats positifs de l’étude de phase 3 AB07015, annoncés le 7 novembre dernier.Les prochaines étapes du développement du masitinib dans l’asthme.Cette présentation sera...

HERZLIYA, Israel, Nov. 27, 2019 (GLOBE NEWSWIRE) — Safe-T® Group Ltd. (Nasdaq, TASE: SFET), a provider of secure access solutions for the hybrid cloud, today announced its financial results for the third quarter and nine-month period ended September 30, 2019.Safe-T reported revenues for the three-month period ended September 30, 2019 totaled $1,349,000, an increase of 444% compared to $248,000 in the three-month period ended September 30, 2018.Revenues for the nine-month period ended September 30, 2019 totaled $2,170,000, an increase of 116% compared to $1,003,000 in the nine-month period ended September 30, 2018.The Company’s cash balance at the end of the quarter was $973,000. In the fourth quarter of 2019, the Company raised gross funds of $4,000,000 through equity and debentures. See further details under “Recent Developments”...

FAIRFIELD, Conn., Nov. 27, 2019 (GLOBE NEWSWIRE) —UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-KCURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (Date of earliest event reported) November 24, 2019Registrant’s telephone number, including area code (617) 443-3000Securities registered pursuant to Section 12(b) of the Act:Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company If...

LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to its CEO, Dr. Jan-Anders Karlsson, under and in accordance with Verona Pharma’s 2017 Incentive Award Plan (which is set out in Verona Pharma’s 2018 annual report and 20-F) (the “Options”).The Options have an exercise price of £0.445 per Ordinary Share, being the closing mid-market price on November 25, 2019. The Options will vest over two different periods following the grant date:  250,000 of the options will vest in three substantially equal annual instalments and the other half of the Options will vest in four substantially equal annual...

Den nyetablerede afdeling Falcon Brighter Future (ISIN-kode DK0061152840) havde tegningsperiode fra den 11. november til og med den 22. november 2019.Resultatet af tegningen fremgår nedenfor:Afdelingen har første handelsdag den 29. november 2019.Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00.Med venlig hilsen

PRESS RELEASENovember 27, 2019The Annual General Meeting on May 29, 2019, resolved that a Nomination Committee shall be appointed before coming election and remuneration. The Nomination Committee shall comprise three members, which should be representative for the two largest shareholders as of last September, together with the Chairman of the Board of Directors.On September 30, 2019, the two largest shareholders, which desired to appoint a representative to the Nomination Committee, were Jørgen Drejer and Thomas Feldthus. Each such shareholder has appointed a representative, as shown below, who together with the Chairman of the Board of Directors will form Saniona AB’s Nomination Committee.The Nomination Committee’s member are:Søren Skjærbæk, Partner at Ursus law firm, Vejle, Denmark, appointed by Jørgen DrejerJohn Haurum, professional...

PRESS RELEASE27 november 2019Vid bolagets årsstämma den 29 maj 2019 beslutades att en valberedning ska utses inför kommande val och arvodering. Valberedningen ska bestå av tre ledamöter, vilka ska representera de två största aktieägarna per september föregående år, tillsammans med ordföranden i styrelsen.Den 30 september 2019 var de två största ägarna som önskar utse en representant till valberedningen Jørgen Drejer och Thomas Feldthus, som i sin egenskap av största aktieägare har utsett representant, enligt nedan, som tillsammans med ordföranden i styrelsen kommer att utgöra Saniona AB:s valberedning.Valberedningens medlemmar är:Søren Skjærbæk, partner på Ursus law firm, Vejle, Danmark, utsedd av Jørgen DrejerJohn Haurum, professionell styrelseledamot i life science bolag och tidigare vd för F-star Biotechnology Limited, Cambridge, Storbritannien,...